Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study
Background Anticholinergic medications are now widely acknowledged for their unfavorable risk-to-benefit profile owing to their adverse effects. Health-related quality of life (HRQoL) is commonly regarded as a crucial person-centered outcome. Aim This study aimed to investigate the association betwe...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical pharmacy 2024-12, Vol.46 (6), p.1352-1361 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1361 |
|---|---|
| container_issue | 6 |
| container_start_page | 1352 |
| container_title | International journal of clinical pharmacy |
| container_volume | 46 |
| creator | Gebreyohannes, Eyob Alemayehu Shibe, Biniam Siyum Taye, Wagaye Atalay Lee, Kenneth Abdela, Ousman Abubeker Ayele, Emneteab Mesfin Belachew, Eyayaw Ashete Mengistu, Segenet Bizuneh Myint, Phyo Kyaw Soiza, Roy Louis |
| description | Background
Anticholinergic medications are now widely acknowledged for their unfavorable risk-to-benefit profile owing to their adverse effects. Health-related quality of life (HRQoL) is commonly regarded as a crucial person-centered outcome.
Aim
This study aimed to investigate the association between anticholinergic burden and HRQoL in hospitalized and ambulatory patients seen in Ethiopia.
Method
This cross-sectional study utilized a questionnaire and medical records to collect data from a convenience sample of adult patients attending both inpatient wards and ambulatory clinic of University of Gondar Comprehensive Specialized Hospital between April and September 2022. Anticholinergic burden was measured by anticholinergic cognitive burdens scale (ACBS), while HRQoL was measured using EQ5D-index (Euroqol-5 dimensions-5-Levels index) and EQ5D-VAS (visual analogue scale). Linear regression was used to assess the influence of high anticholinergic burden (ACBS score ≥ 3) on EQ5D-index and EQ5D-VAS, with adjustments made for sociodemographic and clinical confounders.
Results
A total of 828 patients participated in this study (median (IQR) age was 45.0 (30, 60) and 55.9% were female). On multiple linear regression analysis, high anticholinergic burden was associated with a statistically significant decline in HRQoL, as evidenced by reductions in both EQ5D index (− 0.174 (− 0.250, − 0.098)) and EQ5D-VAS scores (− 9.4 (− 13.3, − 5.2)).
Conclusion
A significant association between high anticholinergic burden and diminished HRQoL was found among a relatively younger cohort in a resource-limited setting, even after adjustment for important confounding variables. Clinicians should be cognizant of the cumulative impact of anticholinergic burden on HRQoL outcomes and strive to minimize anticholinergic burden. |
| doi_str_mv | 10.1007/s11096-024-01769-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11576878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A816837887</galeid><sourcerecordid>A816837887</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-a3c7fba8271462fbcde906477cccedb3cc23807cf39dba0571a8a1ea02ebd88d3</originalsourceid><addsrcrecordid>eNp9kk9v1DAQxSMEolXpF-CALHHhkmLH2djhglYV_6RKXOBsTexJ1pVjb20HaXvne-Ptli1FiPgQy_N7z57Rq6qXjF4wSsXbxBjtu5o2bU2Z6Pr69kl12jSM1kIw9vS4p_ykOk_pmpav7Rq2ap9XJ7wvFn3fnFY_1z5bvQnOeoyT1WRYokFPwBuyQXB5U0d0kNGQmwWczTsSRuLsiATm4CcCZnGZbCFb9DkRW6QkYgpL1Fg7O9u9NGHO1k_vSk3HkFKdUGcbPDiS8mJ2L6pnI7iE5_f_s-r7xw_fLj_XV18_fblcX9Waiz7XwLUYB5CNYKWVcdAGe9q1Qmit0Qxc64ZLKvTIezMAXQkGEhgCbXAwUhp-Vr0_-G6XYUajy5MjOLWNdoa4UwGselzxdqOm8EMxthKdFLI4vLl3iOFmwZTVbJNG58BjWJLiVNKOS972BX39F3pdplJ6LhTjdNUWcvVATeBQWT-GcrHem6q1ZJ3kQkpRqIt_UGUZnK0OHkdbzh8JmoPgbt4Rx2OTjKp9gNQhQKoESN0FSN0W0as_x3OU_I5LAfgBSKXkJ4wPLf3H9hfVVtP5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130548065</pqid></control><display><type>article</type><title>Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gebreyohannes, Eyob Alemayehu ; Shibe, Biniam Siyum ; Taye, Wagaye Atalay ; Lee, Kenneth ; Abdela, Ousman Abubeker ; Ayele, Emneteab Mesfin ; Belachew, Eyayaw Ashete ; Mengistu, Segenet Bizuneh ; Myint, Phyo Kyaw ; Soiza, Roy Louis</creator><creatorcontrib>Gebreyohannes, Eyob Alemayehu ; Shibe, Biniam Siyum ; Taye, Wagaye Atalay ; Lee, Kenneth ; Abdela, Ousman Abubeker ; Ayele, Emneteab Mesfin ; Belachew, Eyayaw Ashete ; Mengistu, Segenet Bizuneh ; Myint, Phyo Kyaw ; Soiza, Roy Louis</creatorcontrib><description>Background
Anticholinergic medications are now widely acknowledged for their unfavorable risk-to-benefit profile owing to their adverse effects. Health-related quality of life (HRQoL) is commonly regarded as a crucial person-centered outcome.
Aim
This study aimed to investigate the association between anticholinergic burden and HRQoL in hospitalized and ambulatory patients seen in Ethiopia.
Method
This cross-sectional study utilized a questionnaire and medical records to collect data from a convenience sample of adult patients attending both inpatient wards and ambulatory clinic of University of Gondar Comprehensive Specialized Hospital between April and September 2022. Anticholinergic burden was measured by anticholinergic cognitive burdens scale (ACBS), while HRQoL was measured using EQ5D-index (Euroqol-5 dimensions-5-Levels index) and EQ5D-VAS (visual analogue scale). Linear regression was used to assess the influence of high anticholinergic burden (ACBS score ≥ 3) on EQ5D-index and EQ5D-VAS, with adjustments made for sociodemographic and clinical confounders.
Results
A total of 828 patients participated in this study (median (IQR) age was 45.0 (30, 60) and 55.9% were female). On multiple linear regression analysis, high anticholinergic burden was associated with a statistically significant decline in HRQoL, as evidenced by reductions in both EQ5D index (− 0.174 (− 0.250, − 0.098)) and EQ5D-VAS scores (− 9.4 (− 13.3, − 5.2)).
Conclusion
A significant association between high anticholinergic burden and diminished HRQoL was found among a relatively younger cohort in a resource-limited setting, even after adjustment for important confounding variables. Clinicians should be cognizant of the cumulative impact of anticholinergic burden on HRQoL outcomes and strive to minimize anticholinergic burden.</description><identifier>ISSN: 2210-7703</identifier><identifier>ISSN: 2210-7711</identifier><identifier>EISSN: 2210-7711</identifier><identifier>DOI: 10.1007/s11096-024-01769-z</identifier><identifier>PMID: 39007992</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Anticholinergics ; Cholinergic Antagonists - adverse effects ; Clinics ; Cross-Sectional Studies ; Ethiopia - epidemiology ; Female ; Health aspects ; Hospitalization - statistics & numerical data ; Humans ; Internal Medicine ; Male ; Medical records ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Middle Aged ; Patients ; Pharmacy ; Quality of Life ; Regression analysis ; Research Article ; Resource-Limited Settings ; Statistical analysis ; Surveys and Questionnaires</subject><ispartof>International journal of clinical pharmacy, 2024-12, Vol.46 (6), p.1352-1361</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 Springer</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-a3c7fba8271462fbcde906477cccedb3cc23807cf39dba0571a8a1ea02ebd88d3</cites><orcidid>0000-0002-0075-4553</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11096-024-01769-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11096-024-01769-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39007992$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gebreyohannes, Eyob Alemayehu</creatorcontrib><creatorcontrib>Shibe, Biniam Siyum</creatorcontrib><creatorcontrib>Taye, Wagaye Atalay</creatorcontrib><creatorcontrib>Lee, Kenneth</creatorcontrib><creatorcontrib>Abdela, Ousman Abubeker</creatorcontrib><creatorcontrib>Ayele, Emneteab Mesfin</creatorcontrib><creatorcontrib>Belachew, Eyayaw Ashete</creatorcontrib><creatorcontrib>Mengistu, Segenet Bizuneh</creatorcontrib><creatorcontrib>Myint, Phyo Kyaw</creatorcontrib><creatorcontrib>Soiza, Roy Louis</creatorcontrib><title>Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study</title><title>International journal of clinical pharmacy</title><addtitle>Int J Clin Pharm</addtitle><addtitle>Int J Clin Pharm</addtitle><description>Background
Anticholinergic medications are now widely acknowledged for their unfavorable risk-to-benefit profile owing to their adverse effects. Health-related quality of life (HRQoL) is commonly regarded as a crucial person-centered outcome.
Aim
This study aimed to investigate the association between anticholinergic burden and HRQoL in hospitalized and ambulatory patients seen in Ethiopia.
Method
This cross-sectional study utilized a questionnaire and medical records to collect data from a convenience sample of adult patients attending both inpatient wards and ambulatory clinic of University of Gondar Comprehensive Specialized Hospital between April and September 2022. Anticholinergic burden was measured by anticholinergic cognitive burdens scale (ACBS), while HRQoL was measured using EQ5D-index (Euroqol-5 dimensions-5-Levels index) and EQ5D-VAS (visual analogue scale). Linear regression was used to assess the influence of high anticholinergic burden (ACBS score ≥ 3) on EQ5D-index and EQ5D-VAS, with adjustments made for sociodemographic and clinical confounders.
Results
A total of 828 patients participated in this study (median (IQR) age was 45.0 (30, 60) and 55.9% were female). On multiple linear regression analysis, high anticholinergic burden was associated with a statistically significant decline in HRQoL, as evidenced by reductions in both EQ5D index (− 0.174 (− 0.250, − 0.098)) and EQ5D-VAS scores (− 9.4 (− 13.3, − 5.2)).
Conclusion
A significant association between high anticholinergic burden and diminished HRQoL was found among a relatively younger cohort in a resource-limited setting, even after adjustment for important confounding variables. Clinicians should be cognizant of the cumulative impact of anticholinergic burden on HRQoL outcomes and strive to minimize anticholinergic burden.</description><subject>Adult</subject><subject>Aged</subject><subject>Anticholinergics</subject><subject>Cholinergic Antagonists - adverse effects</subject><subject>Clinics</subject><subject>Cross-Sectional Studies</subject><subject>Ethiopia - epidemiology</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical records</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Pharmacy</subject><subject>Quality of Life</subject><subject>Regression analysis</subject><subject>Research Article</subject><subject>Resource-Limited Settings</subject><subject>Statistical analysis</subject><subject>Surveys and Questionnaires</subject><issn>2210-7703</issn><issn>2210-7711</issn><issn>2210-7711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kk9v1DAQxSMEolXpF-CALHHhkmLH2djhglYV_6RKXOBsTexJ1pVjb20HaXvne-Ptli1FiPgQy_N7z57Rq6qXjF4wSsXbxBjtu5o2bU2Z6Pr69kl12jSM1kIw9vS4p_ykOk_pmpav7Rq2ap9XJ7wvFn3fnFY_1z5bvQnOeoyT1WRYokFPwBuyQXB5U0d0kNGQmwWczTsSRuLsiATm4CcCZnGZbCFb9DkRW6QkYgpL1Fg7O9u9NGHO1k_vSk3HkFKdUGcbPDiS8mJ2L6pnI7iE5_f_s-r7xw_fLj_XV18_fblcX9Waiz7XwLUYB5CNYKWVcdAGe9q1Qmit0Qxc64ZLKvTIezMAXQkGEhgCbXAwUhp-Vr0_-G6XYUajy5MjOLWNdoa4UwGselzxdqOm8EMxthKdFLI4vLl3iOFmwZTVbJNG58BjWJLiVNKOS972BX39F3pdplJ6LhTjdNUWcvVATeBQWT-GcrHem6q1ZJ3kQkpRqIt_UGUZnK0OHkdbzh8JmoPgbt4Rx2OTjKp9gNQhQKoESN0FSN0W0as_x3OU_I5LAfgBSKXkJ4wPLf3H9hfVVtP5</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Gebreyohannes, Eyob Alemayehu</creator><creator>Shibe, Biniam Siyum</creator><creator>Taye, Wagaye Atalay</creator><creator>Lee, Kenneth</creator><creator>Abdela, Ousman Abubeker</creator><creator>Ayele, Emneteab Mesfin</creator><creator>Belachew, Eyayaw Ashete</creator><creator>Mengistu, Segenet Bizuneh</creator><creator>Myint, Phyo Kyaw</creator><creator>Soiza, Roy Louis</creator><general>Springer International Publishing</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0075-4553</orcidid></search><sort><creationdate>20241201</creationdate><title>Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study</title><author>Gebreyohannes, Eyob Alemayehu ; Shibe, Biniam Siyum ; Taye, Wagaye Atalay ; Lee, Kenneth ; Abdela, Ousman Abubeker ; Ayele, Emneteab Mesfin ; Belachew, Eyayaw Ashete ; Mengistu, Segenet Bizuneh ; Myint, Phyo Kyaw ; Soiza, Roy Louis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-a3c7fba8271462fbcde906477cccedb3cc23807cf39dba0571a8a1ea02ebd88d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anticholinergics</topic><topic>Cholinergic Antagonists - adverse effects</topic><topic>Clinics</topic><topic>Cross-Sectional Studies</topic><topic>Ethiopia - epidemiology</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical records</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Pharmacy</topic><topic>Quality of Life</topic><topic>Regression analysis</topic><topic>Research Article</topic><topic>Resource-Limited Settings</topic><topic>Statistical analysis</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gebreyohannes, Eyob Alemayehu</creatorcontrib><creatorcontrib>Shibe, Biniam Siyum</creatorcontrib><creatorcontrib>Taye, Wagaye Atalay</creatorcontrib><creatorcontrib>Lee, Kenneth</creatorcontrib><creatorcontrib>Abdela, Ousman Abubeker</creatorcontrib><creatorcontrib>Ayele, Emneteab Mesfin</creatorcontrib><creatorcontrib>Belachew, Eyayaw Ashete</creatorcontrib><creatorcontrib>Mengistu, Segenet Bizuneh</creatorcontrib><creatorcontrib>Myint, Phyo Kyaw</creatorcontrib><creatorcontrib>Soiza, Roy Louis</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gebreyohannes, Eyob Alemayehu</au><au>Shibe, Biniam Siyum</au><au>Taye, Wagaye Atalay</au><au>Lee, Kenneth</au><au>Abdela, Ousman Abubeker</au><au>Ayele, Emneteab Mesfin</au><au>Belachew, Eyayaw Ashete</au><au>Mengistu, Segenet Bizuneh</au><au>Myint, Phyo Kyaw</au><au>Soiza, Roy Louis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study</atitle><jtitle>International journal of clinical pharmacy</jtitle><stitle>Int J Clin Pharm</stitle><addtitle>Int J Clin Pharm</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>46</volume><issue>6</issue><spage>1352</spage><epage>1361</epage><pages>1352-1361</pages><issn>2210-7703</issn><issn>2210-7711</issn><eissn>2210-7711</eissn><abstract>Background
Anticholinergic medications are now widely acknowledged for their unfavorable risk-to-benefit profile owing to their adverse effects. Health-related quality of life (HRQoL) is commonly regarded as a crucial person-centered outcome.
Aim
This study aimed to investigate the association between anticholinergic burden and HRQoL in hospitalized and ambulatory patients seen in Ethiopia.
Method
This cross-sectional study utilized a questionnaire and medical records to collect data from a convenience sample of adult patients attending both inpatient wards and ambulatory clinic of University of Gondar Comprehensive Specialized Hospital between April and September 2022. Anticholinergic burden was measured by anticholinergic cognitive burdens scale (ACBS), while HRQoL was measured using EQ5D-index (Euroqol-5 dimensions-5-Levels index) and EQ5D-VAS (visual analogue scale). Linear regression was used to assess the influence of high anticholinergic burden (ACBS score ≥ 3) on EQ5D-index and EQ5D-VAS, with adjustments made for sociodemographic and clinical confounders.
Results
A total of 828 patients participated in this study (median (IQR) age was 45.0 (30, 60) and 55.9% were female). On multiple linear regression analysis, high anticholinergic burden was associated with a statistically significant decline in HRQoL, as evidenced by reductions in both EQ5D index (− 0.174 (− 0.250, − 0.098)) and EQ5D-VAS scores (− 9.4 (− 13.3, − 5.2)).
Conclusion
A significant association between high anticholinergic burden and diminished HRQoL was found among a relatively younger cohort in a resource-limited setting, even after adjustment for important confounding variables. Clinicians should be cognizant of the cumulative impact of anticholinergic burden on HRQoL outcomes and strive to minimize anticholinergic burden.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>39007992</pmid><doi>10.1007/s11096-024-01769-z</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-0075-4553</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2210-7703 |
| ispartof | International journal of clinical pharmacy, 2024-12, Vol.46 (6), p.1352-1361 |
| issn | 2210-7703 2210-7711 2210-7711 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11576878 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Anticholinergics Cholinergic Antagonists - adverse effects Clinics Cross-Sectional Studies Ethiopia - epidemiology Female Health aspects Hospitalization - statistics & numerical data Humans Internal Medicine Male Medical records Medical research Medicine Medicine & Public Health Medicine, Experimental Middle Aged Patients Pharmacy Quality of Life Regression analysis Research Article Resource-Limited Settings Statistical analysis Surveys and Questionnaires |
| title | Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T09%3A19%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anticholinergic%20burden%20and%20health-related%20quality%20of%20life%20among%20adult%20patients%20in%20a%20resource-limited%20setting:%20a%20cross-sectional%20study&rft.jtitle=International%20journal%20of%20clinical%20pharmacy&rft.au=Gebreyohannes,%20Eyob%20Alemayehu&rft.date=2024-12-01&rft.volume=46&rft.issue=6&rft.spage=1352&rft.epage=1361&rft.pages=1352-1361&rft.issn=2210-7703&rft.eissn=2210-7711&rft_id=info:doi/10.1007/s11096-024-01769-z&rft_dat=%3Cgale_pubme%3EA816837887%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130548065&rft_id=info:pmid/39007992&rft_galeid=A816837887&rfr_iscdi=true |